UNSPSC 51314325: Brompheniramine/phenylephrine/phenyltoloxamine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE501. This VA Drug Class (RE501) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT.

UNSPSC 51314325 Brompheniramine/phenylephrine/phenyltoloxamine is a Commodity code that does not align with the recent state and local procurement activity tagged under it. The three most recent opportunities reflect purchases of naloxone and drug deactivation systems, therapeutic pharmacy initiative direct-to-manufacturer prescriptions, and generic multi-source pharmaceuticals and over-the-counter products — none of which are brompheniramine-combination antihistamines or the specific pharmaceutical formulation the code nominally describes. The code shows little relevant recent activity under its stated scope.

The mismatch between the code's name and actual procurement practice suggests either tagging error in the state and local system or that brompheniramine/phenylephrine/phenyltoloxamine products are sourced through broader pharmaceutical supply contracts (such as the MMCAP generic multi-source pharmaceuticals RFP or wholesaler agreements) rather than as standalone commodity purchases. Entities including Seminole County, Florida; the Texas Health and Human Services Commission; and the Minnesota Multistate Cooperative Purchasing Alliance are actively procuring pharmaceuticals and pharmacy services, but none explicitly solicit the brompheniramine formulation as a line item. Businesses pursuing this code should verify with individual issuing bodies whether brompheniramine-combination products are included in their open pharmaceutical or OTC solicitations, or clarify the correct UNSPSC code mapping for their offering.